Accuracy of five on-site immunoassay drugs-of-abuse testing devices.
Many current "on-site" urine drug-testing products claim performance equivalent to laboratory testing. Five commercially available products (PharmScreen, Roche TestCup, Accusign DOA 2, Status DS, and American Bio Medica-Rapid Drug Screen) were challenged with quality-control specimens of known drug metabolite concentrations, 25% above and 25% below the SAMHSA cutoffs, and with known positive and negative donor specimens previously analyzed by immunoassay and gas chromatography-mass spectrometry. The results indicate discrepancies between claims and performance for all products, particularly with amphetamines. The implications for employer-based drug testing are discussed.
Taylor
E H
EH
National Safety Alliance, Nashville, Tennessee, 37211, USA.
Oertli
E H
EH
Wolfgang
J W
JW
Mueller
E
E
D004347:Drug Interactions; D008401:Gas Chromatography-Mass Spectrometry; D017408:Guidelines as Topic; D006801:Humans; D013287:Illicit Drugs / Q000652:urine*; D007118:Immunoassay / Q000295:instrumentation* / Q000379:methods; D011786:Quality Control; D012680:Sensitivity and Specificity; D015813:Substance Abuse Detection / Q000379:methods*; D014481:United States; D014482:United States Substance Abuse and Mental Health Services Administration / Q000592:standards
D013287:Illicit Drugs